Multiple Sclerosis News Today

Multiple Sclerosis News Today is an online news platform focused on providing in-depth daily updates about Multiple Sclerosis (MS).

National

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#372973

United States

#112995

Health/Health Conditions and Concerns

#260

Traffic sources

Monthly visitors

Articles

MS therapy PoNS device OK'd for reimbursement by United Healthcare

1 day ago | multiplesclerosisnewstoday.com | Lila Levinson

The PoNS device has shown significant benefits in walking and balance in clinical trials, and benefits were seen in real-world studies.
B-cell levels can predict PIRA in relapsing MS patients on Ocrevus

6 days ago | multiplesclerosisnewstoday.com | Marisa Wexler

In people with relapsing forms of multiple sclerosis (MS) treated with Ocrevus (ocrelizumab), levels of B-cells can help to predict the risk of progression independent of relapse activity, a new study reports. “Our results unveil a discernible relationship between the degree of B-cell depletion and disease progression in individuals with [relapsing] MS,” researchers wrote.
Intrathecal methotrexate halts disability worsening, data show

1 week ago | multiplesclerosisnewstoday.com | Margarida Maia

Injections of methotrexate into the spinal canal given every three months were safe and well tolerated, and helped adults with progressive forms of multiple sclerosis (MS) maintain stable disease levels for up to nine years. That’s according to data from a small, open-label Phase 1 clinical study (NCT02644044) that tested how safe and well tolerated intrathecal methotrexate is and how well it works to slow disability worsening in people with primary or secondary progressive MS.
Foralumab shows promise in early study of nonactive SPMS

1 week ago | multiplesclerosisnewstoday.com | Marisa Wexler

Foralumab was well tolerated in people with nonactive secondary progressive multiple sclerosis (SPMS), according to data from a small, open-label study conducted under an expanded access program. The therapy, being developed by Tiziana Life Sciences, also eased fatigue and lessened disability in some participants. The promising findings formed the basis for a Phase 2a study (NCT06292923) that’s currently testing foralumab against a placebo in adults with nonactive SPMS.
Certain spinal cord lesions may be markers of early MS damage

1 week ago | multiplesclerosisnewstoday.com | Marisa Wexler

Certain lesions in the spinal cords of people with multiple sclerosis (MS) show damage to nerve fibers despite having normal myelin, according to a study done on postmortem samples using powerful MRI scans paired with detailed tissue analyses.
Broad rim lesions identified as MS disease progression marker

1 week ago | multiplesclerosisnewstoday.com | Marisa Wexler

Wider rims of immune cells surrounding multiple sclerosis (MS) lesions in the brain and spinal cord are associated with faster disease progression, a new study shows. Monitoring this type of lesion may help track MS disease progression and measure how the disease is responding to treatment, and the findings may help guide the development of new strategies for MS therapy, the researchers said.
Vidofludimus calcium lowers risk of progressive MS disability worsening

1 week ago | multiplesclerosisnewstoday.com | Margarida Maia

Vidofludimus calcium, an experimental oral therapy from Immunic Therapeutics, reduced the risk of confirmed disability worsening and slowed brain shrinkage in people with progressive forms of multiple sclerosis (MS). That’s according to top-line data from CALLIPER (NCT05054140), a Phase 2 clinical trial testing a daily dose of it against a placebo in 467 adults with progressive MS who hadn’t had a relapse in the two years before enrolling.
Multiple Sclerosis Association of America to host annual Improving Lives Benefit

1 week ago | multiplesclerosisnewstoday.com | Andrea Lobo

The Multiple Sclerosis Association of America (MSAA) will host its 11th annual Improving Lives Benefit on May 14 to bring together members of the multiple sclerosis (MS) community, celebrate achievements, and raise support for the organization’s free programs and services. The fundraising event will take place at the Barnes Foundation in Philadelphiaand will also be live-streamed.
Thyroid hormone FT4 may be risk factor for MS: Study

2 weeks ago | multiplesclerosisnewstoday.com | Steve Bryson

The thyroid hormone thyroxine, or FT4, may play an indirect role in the development of multiple sclerosis (MS), which seems to be mediated by certain immune cells, a study suggests. “Future investigations should explore how these immune cells modulate MS onset and progression in the context of thyroid dysfunction, and how targeting these cells could lead to innovative MS interventions,” researchers wrote.
Resistance training program didn't cut cardiovascular risk in SPMS

2 weeks ago | multiplesclerosisnewstoday.com | Andrea Lobo

While a four-month progressive resistance training program improved muscle strength in people with secondary progressive multiple sclerosis (SPMS) in the Netherlands, it did not significantly change their risk of developing cardiovascular disease, a small study showed. Individual cardiovascular risk factors and 10-year risk estimation tools showed no significant changes after the training program.